Amylyx Pharmaceuticals, Inc. Unrecorded Unconditional Purchase Obligation, to be Paid, Remainder of Fiscal Year
Amylyx Pharmaceuticals, Inc. (AMLX) had Unrecorded Unconditional Purchase Obligation, to be Paid, Remainder of Fiscal Year of $35.00 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Commitment and Contingencies › Unconditional Purchase Obligations (Excluding Capital Stock Redemptions)
us-gaap:UnrecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear · last filed 2026-08-06
- 2026-06-30: Unrecorded Unconditional Purchase Obligation, to be Paid, Remainder of Fiscal Year $35.00M.
| Period end | Unrecorded Unconditional Purchase Obligation, to be Paid, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $35.00M 10-Q · filed 2026-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |